Basic Information
| LncRNA/CircRNA Name | LOC554202 |
| Synonyms | MIR31HG, hsa-lnc-31, LncHIFCAR |
| Region | GRCh38_9:21455642-21559669 |
| Ensemble | ENSG00000171889 |
| Refseq | NR_027054 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Gefitinib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc |
| Sample | subcutaneous tumor tissues,cell lines(PC9 and HCC827) |
| Expression Pattern | up-regulated |
| Function Description | Furthermore, both LOC554202 and miR-31 levels were significantly increased in NSCLC patients acquiring resistance to gefitinib, and the expression of LOC554202 was positively correlated with the expression of miR-31. By luciferase reporter assays, we identified RAS P21 Protein Activator 1 (RASA1) and Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor (FIH-1) as direct targets of miR-31 in NSCLC cells. Mechanistically, miR-31 directly repressed RASA1 and FIH-1 expression, and thus, at least partially activated the RAF-MEK-ERK and PI3K-AKT signaling pathways in NSCLC with acquired resistance to gefitinib. |
| Pubmed ID | 31762810 |
| Year | 2019 |
| Title | Long Non-Coding RNA LOC554202 Promotes Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Through Upregulating miR-31 Expression |
External Links
| Links for LOC554202 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |